Protein Discovery Announces Development Partnership with LEAP Technologies
News Apr 19, 2006
The partnership will focus on developing and commercializing a MALDI matrix sprayer for tissue imaging mass spectrometry.
Tissue imaging mass spectrometry is a method of proteomics and drug metabolism analysis developed in the Caprioli Research Laboratory in the Mass Spectrometry Research Center of the Vanderbilt Medical Center and licensed to Protein Discovery.
The technology is designed to enable direct spectrometric analysis of tissues, yielding specific, spatially resolved molecular profiles of targeted regions.
Data from these analyses may form prognostic or diagnostic markers of disease, or reveal potential therapeutic and toxic effects of drug compounds prior to clinical testing.
The technology can also help pharmaceutical researchers determine the metabolic processing of new drug compounds and whether the compounds are successfully reaching targeted tissues.
Chuck Witkowski, president and chief executive officer of Protein Discovery, said, "We believe that the MALDI matrix sprayer under development by LEAP Technologies represents a significant step forward for tissue imaging mass spectrometry."
"In contrast to existing MALDI matrix deposition techniques that deposit a series of small droplets, the sprayer has the potential to deliver a marked increase in resultant pixel resolution, throughput, and reproducibility."
"This is the only automated system available for MALDI matrix spray coating and we are pleased to assist in its development and optimization."
Werner Martin, president and chief executive officer of LEAP Technologies added, "Protein Discovery is the ideal development partner for this product. They are the industryÕs exclusive service provider for tissue imaging mass spectrometry and have unique application expertise."
"We are very pleased to be working with Protein Discovery to soon provide the industry with an automated matrix spraying instrument for preparing tissue for direct analysis via mass spectrometry in a highly reproducible and sensitive manner. LEAP already offers a matrix on tissue printing device."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE